前列腺切除术后大分割放疗减少毒性并提高便利性:1/2期试验
这项多中心1/2期研究旨在确定前列腺床大分割放疗作为挽救或辅助治疗时毒性可接受的最短剂量分割方案,并评估其健康相关生活质量。结果显示42.6 Gy/10次为毒性可接受的最短方案,但2-3级泌尿生殖和胃肠道毒性发生率高于预期,且肠道生活质量下降。
要点
- 42.6 Gy/10次被确定为毒性可接受的最短大分割方案。
- 2-3级泌尿生殖和胃肠道毒性发生率高于预期。
- 直肠最热25%区域剂量较高与2级以上胃肠道毒性风险增加相关。
核心结论
- 42.6 Gy/10次是本研究中毒性可接受的最短剂量分割方案。
- 该方案2-3级泌尿生殖和胃肠道毒性发生率高于预期,且EPIC肠道生活质量域下降。
研究设计与样本
- 多中心1/2期研究,1期部分确定毒性可接受的最短剂量分割方案,2期部分评估生活质量。
- 患者接受三种每日放疗方案之一:56.6 Gy/20次、50.4 Gy/15次或42.6 Gy/10次。
- 不允许区域淋巴结照射和雄激素剥夺治疗,治疗后随访2年。
主要发现
- 32例可评估患者,中位随访3.53年,大多数患者(23例)接受42.6 Gy/10次方案。
- 3级泌尿生殖毒性发生于3例患者,3级胃肠道毒性发生于1例患者,另有1例4级脓毒症事件。
- 直肠最热25%区域剂量较高与2级以上胃肠道毒性风险增加相关,未发现预测泌尿生殖毒性的剂量学因素。
- 与基线相比,1年时肠道生活质量平均评分显著下降,膀胱生活质量评分无显著变化。
- 前列腺特异性抗原失败(定义为最低点加2 ng/mL)发生于34.3%的患者,转移更常见于区域淋巴结(7例中5例)而非骨骼(7例中2例),治疗期间患者平均自付费用为223.90美元。
关键数值与推荐
- 42.6 Gy/10次为毒性可接受的最短剂量分割方案。
- 3级泌尿生殖毒性3例,3级胃肠道毒性1例,4级脓毒症1例。
- 前列腺特异性抗原失败率34.3%(定义:最低点加2 ng/mL)。
- 转移部位:区域淋巴结5/7,骨骼2/7。
- 治疗期间平均自付费用223.90美元。
临床怎么用
- 前列腺切除术后辅助或挽救放疗可考虑42.6 Gy/10次大分割方案,但需注意2-3级泌尿生殖和胃肠道毒性风险高于预期。
- 制定计划时关注直肠最热25%区域剂量,以降低2级以上胃肠道毒性风险。
- 治疗前应告知患者肠道生活质量可能下降及自付费用。
局限性
- 样本量较小(32例可评估患者)。
- 随访时间有限(中位3.53年)。
- 不允许区域淋巴结照射和雄激素剥夺治疗,可能限制结论外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase 1 portion of this multicenter, phase 1/2 study of hypofractionated (HypoFx) prostate bed radiation therapy (RT) as salvage or adjuvant therapy aimed to identify the shortest dose-fractionation schedule with acceptable toxicity. The phase 2 portion aimed to assess the health-related quality of life (QoL) of using this HypoFx regimen. METHODS AND MATERIALS: Eligibility included standard adjuvant or salvage prostate bed RT indications. Patients were assigned to receive 1 of 3 daily RT schedules: 56.6 Gy in 20 Fx, 50.4 Gy in 15 Fx, or 42.6 Gy in 10 Fx. Regional nodal irradiation and androgen deprivation therapy were not allowed. Participants were followed for 2 years after treatment with outcome measures based on prostate-specific antigen levels, toxicity assessments (Common Terminology Criteria for Adverse Events, v4.0), QoL measures (the Expanded Prostate Cancer Index Composite [EPIC] and EuroQol EQ-5D instruments), and out-of-pocket costs. RESULTS: There were 32 evaluable participants, and median follow-up was 3.53 years. The shortest dose-fractionation schedule with acceptable toxicity was determined to be 42.6 Gy in 10 Fx, with most patients (23) treated with this schedule. Grade 3 genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 3 patients and 1 patient, respectively. There was 1 grade 4 sepsis event. Higher dose to the hottest 25% of the rectum was associated with increased risk of grade 2+ GI toxicity; no dosimetric factors were found to predict for GU toxicity. There was a significant decrease in the mean bowel, but not bladder, QoL score at 1 year compared with baseline. Prostate-specific antigen failure occurred in 34.3% of participants, using a definition of nadir plus 2 ng/mL. Metastases were more likely to occur in regional lymph nodes (5 of 7) than in bones (2 of 7). The mean out-of-pocket cost for patients during treatment was $223.90. CONCLUSIONS: We identified 42.6 Gy in 10 fractions as the shortest dose-fractionation schedule with acceptable toxicity in this phase 1/2 study. There was a higher than expected rate of grade 2 to 3 GU and GI toxicity and a decreased EPIC bowel QoL domain with this regimen. Future studies are needed to explore alternative adjuvant/salvage HypoFx RT schedules after radical prostatectomy.
引用
- Wages NA, Sanders JC, Smith A, et al. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 33227441. doi:10.1016/j.ijrobp.2020.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。